At the January 2 meeting, the firm presented more data and notably
"requested for consideration of their proposal in the wake of
incidence of new mutated coronavirus infection."
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/how-sec-changed-covaxin-stance/articleshow/80124784.cms
No comments:
Post a Comment